All In Biotech

Drug Trial Radar · NCT05091424

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

A Phase IB Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 332 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

332

Planned (sponsor's estimate)

Start

Mar 7, 2022

Primary completion

Feb 10, 2031

Study completion Feb 10, 2032

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Oct 25, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the safety, tolerability, pharmaokinetics, and preliminary efficacy of mosunetuzumab (Lunsumio) monotherapy in participants with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This study will also allow participants who are currently progressing on a Bruton tyrosine kinase inhibitor (BTKi) and requiring salvage therapy as assessed by the treating physician to continue their BTKi throughout the screening period and for the first three cycles of mosunetuzumab. An additional arm (open to non-US participants only) has been added to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of mosunetuzumab in combination with venetoclax, a B-cell lymphoma 2 (BCL2) inhibitor, compared to standard-of-care rituximab plus venetoclax.

Conditions

  • Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Interventions

  • MosunetuzumabDrug

    Participants will receive subcutaneous (SC) mosunetuzumab.

  • TocilizumabDrug

    Participants will receive intravenous (IV) tocilizumab as needed for cytokine release syndrome (CRS) events.

  • VenetoclaxDrug

    Participants will receive daily oral venetoclax.

  • RituximabDrug

    Participants will receive IV rituximab as per protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Dose-Limiting Toxicities (DLTs)Time frame: From the first administration of mosunetuzumab until 21 days after the final mosunetuzumab step-up dose for Arms A, B, and C (up to 3 months)
  2. Objective Response Rate (ORR) During Dose Expansion PhaseTime frame: Up to 8-12 weeks after the last dose of study drug

Locations

31 sites in 10 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Rochester

    Rochester, Minnesota · Recruiting

  • Memorial Sloan-Kettering Cancer Center

    New York, New York · Withdrawn

  • The James Cancer Hospital and Solove Research Institute

    Columbus, Ohio · Recruiting

  • Uni of Texas - Md Anderson Cancer Center

    Houston, Texas · Withdrawn

  • Huntsman Cancer Institute at The University of Utah

    Salt Lake City, Utah · Recruiting

  • Princess Alexandra Hospital Woolloongabba

    Woolloongabba, Queensland, Australia · Recruiting

  • Peter MacCallum Cancer Center

    East Melbourne, Victoria, Australia · Completed

  • Monash Medical Centre

    Melbourne, Victoria, Australia · Recruiting

  • Peking University People's Hospital

    Beijing, China · Recruiting

  • Southern Medical University Nanfang Hospital

    Guangzhou, China · Recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, China · Recruiting

  • Tianjin Institute of Hematology & Blood Diseases Hospital

    Tianjin, China · Recruiting

  • Chu de Clermont Ferrand

    Clermont-Ferrand, France · Withdrawn

  • IUCT Oncopole

    Toulouse, France · Withdrawn

  • Universitätsklinikum Augsburg

    Augsburg, Germany · Recruiting

  • Uniklinik Koln

    Cologne, Germany · Withdrawn

  • Universitätsklinikum Ulm

    Ulm, Germany · Withdrawn

  • A.O. Spedali Civili Di Brescia-P.O. Spedali Civili

    Brescia, Lombardy, Italy · Recruiting

  • Osp. San Raffaele

    Milan, Lombardy, Italy · Recruiting

  • Asst Grande Ospedale Metropolitano Niguarda

    Milan, Lombardy, Italy · Recruiting

  • Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia

    Sant'Andrea Delle Fratte (PG), Umbria, Italy · Recruiting

  • Uniwersyteckie Centrum Kliniczne

    Gda?sk, Poland · Recruiting

  • PRATIA MCM Kraków

    Krakow, Poland · Recruiting

  • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu

    Wroc?aw, Poland · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • Seoul St Mary's Hospital

    Seoul, South Korea · Recruiting

  • Yeouido St. Mary's Hospital

    Seoul, South Korea · Recruiting

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Spain · Recruiting

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain · Recruiting

  • Christie Hospital NHS Trust

    Manchester, United Kingdom · Recruiting

  • Churchill Hospital

    Oxford, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.